SLC: Plans to establish a joint venture with a biopharmaceutical company, with a registered capital of 50 million yuan

SLC announced that the company plans to jointly establish Shanghai Changlian Baifu Pharmaceutical Co., Ltd. with Shanghai Waigaoqiao Biomedical Industry Development Co., Ltd. The registered capital of the new company is 50 million yuan, of which SLC will contribute 30 million yuan, accounting for 60% of the shares; the biomedical company will contribute 20 million yuan, accounting for 40% of the shares. This investment will not have a significant impact on the company's revenue, profit, or cash flow in the short term. The transaction constitutes a related party transaction but does not constitute a major asset reorganization. This transaction has been approved in advance by the special meeting of the company's independent directors and the audit committee meeting, and has been reviewed and approved by the 12th meeting of the 4th board of directors and the 10th meeting of the 4th supervisory board, and does not need to be submitted to the company's shareholders' meeting for approval